GlycoMimetics (GLYC) Misses Q3 EPS by 2c; Reports Cash and Cash Equivalents of $101.9

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to GlycoMimetics (GLYC) Misses Q3 EPS by 2c; Reports Cash and Cash Equivalents of $101.9

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021

November 2, 2021 7:30 AM EDT

Significant progress achieved for lead investigational drug candidate uproleselan: Robust enrollment momentum in the quarter indicates imminent completion of enrollment for Company-sponsored Phase 3 pivotal trial in patients with relapsed/refractory acute myeloid leukemia (AML); top line results anticipated after year-end 2022 Data showing high rate of Minimal Residual Disease (MRD) in evaluable relapsed/refractory AML patients were published in BLOOD, as part of a comprehensive review of the data set from the Companys Phase 1/2 trial evaluating uproleselan in both relapsed/refractory and newly diagnosed fit for chemo AML patient... More